Acute Myeloid Leukemia (AML) –Tumour Slide Deck 2023

BOSTON - July 20, 2023 - PRLog -- Acute Myeloid Leukemia (AML) –Tumour Slide Deck 2023

There were no approved treatments for decades for acute myeloid leukaemia (AML) other than chemotherapies. The past six years has witnessed the approval of eleven new therapies for AML; Rydapt / midostaurin (Novartis), Vyxeos (CPX-351) / cytarabine/daunorubicin liposomal formulation (Jazz, Nippon Shinyaku), Idhifa / enasidenib (BMS, Servier), Mylotarg / gemtuzumab ozogamicin (UCB, PDL, Pfizer), Tibsovo / ivosidenib (Servier), Venclexta / venetoclax (Roche, AbbVie), Xospata / gilteritinib (Astellas), Daurismo / glasdegib (Pfizer), Vanflyta / quizartinib (Daiichi Sankyo), Onureg (azacitidine oral) and Rezlidhia / olutasidenib (Forma Therapeutics).

How are these agents faring on the market so far and will more personalised treatments follow their lead? All the drugs above form part of a rich pipeline, but which drugs stand out to key opinion leaders (KOLs)? Learn how AML's market is evolving, and how our analyst expects developers to differentiate their pipeline therapies in the Slide Deck: Acute Myeloid Leukaemia.

Key coverage and questions answered…

1. Insights into the AML treatments and relapse patterns observed across G7 countries. Specifically, what are the similarities and differences in epidemiology and treatment patterns between the US, EU, and Japan!
2. As per KOLs, the major unmet needs they have highlighted in the current treatment landscape and specific areas where advancements or improvements are needed?
3. An understanding of the future landscape in the next 3-7 years based on the insights and opinions shared by KOLs. The emerging trends, technologies, or treatment approaches that are expected to have a significant impact in AML space.
4. What is the input provided by KOLs regarding key molecules or drugs in the field? Which specific molecules are generating the most interest and discussion among KOLs, and what potential benefits or challenges do they present?
5. What is the latest data regarding the combination of Venetoclax (Venclexta) and Azacitidine? The notable findings or advancements in this treatment approach.
6. Others....

https://mellalta.com/product/acute-myeloid-leukemia-aml-tumour-slide-deck-2023/